Daniel Morillo

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt et al. · Journal of Clinical Oncology · 2023 · 84 citations

Immunology, Immune Regulation, Immunoediting +23

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Yaël C. Cohen, Hila Magen, Moshe E. Gatt et al. · New England Journal of Medicine · 2025 · 70 citations

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

Bhagirathbhai Dholaria, Katja Weisel, María‐Victoria Mateos et al. · Journal of Clinical Oncology · 2023 · 60 citations

Immune Regulation, Immunology, Pathology +21

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Jennifer R. Diamond, Valentina Boni, Emerson A. Lim et al. · Clinical Cancer Research · 2022 · 52 citations · Full text

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · The Lancet Haematology · 2025 · 51 citations · Full text

Hematological Malignancy, Medicine, Hematology +7